5:42 PM
 | 
Apr 18, 2019
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BMS reports detailed survival data for failed Opdivo maintenance trial in SCLC

Bristol-Myers said Opdivo nivolumab plus Yervoy ipilimumab as maintenance therapy of extensive-stage disease small cell lung cancer following first-line platinum-based chemotherapy led to a median overall survival of 9.2 months vs. 9.6 months for placebo (HR=0.92, 95% CI: 0.75, 1.12, p=0.3693) in the Phase III CheckMate -451 trial.

Bristol-Myers Squibb Co....

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >